Association of dry skin with intercellular lipid composition of stratum corneum after erlotinib administration
- 15 July 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Chemotherapy and Pharmacology
- Vol. 86 (2), 233-243
- https://doi.org/10.1007/s00280-020-04095-z
Abstract
Purpose Erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, causes skin disorders such as dry skin, which impairs the skin barrier function. Stratum corneum (SC) lipids play an important role in skin barrier function; therefore, this study aimed to investigate the relationship between erlotinib-related dry skin and changes in the intercellular lipid composition and structure of the SC. Methods Overall, 21 patients with non-small lung cancer were enrolled in this study. All patients received 150 mg/day erlotinib orally. A SC sample of each patient was collected from the inner forearm using the tape stripping method on days 0, 7, 14, 28, and 56 after erlotinib administration. The intercellular lipid components of ceramide (CER), free fatty acid (FFA), and cholesterol sulfate (CS) in samples extracted from the tape were analyzed using liquid chromatography/time-of-flight/mass spectrometry. SC samples from six healthy subjects were collected as controls on days 0, 28 and 56 and analyzed similarly. Results Although total CER and FFA levels were not changed after erlotinib administration, the levels of CER subclasses [AP] and [AH] and hydroxy FFA, which are structural components of CER subclass [A], decreased. In contrast, the CS levels increased after erlotinib administration. Moreover, higher CS levels in the SC correlated with the clinical condition of dry skin. No changes were observed in the SC lipid composition in healthy subjects. Conclusion Erlotinib-related dry skin was associated with a higher CS level in the SC.Keywords
Funding Information
- the Japan Research Foundation for Clinical Pharmacology (2015A09)
This publication has 43 references indexed in Scilit:
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to ManagementOncology and Therapy, 2017
- Skin problems and EGFR-tyrosine kinase inhibitorJapanese Journal of Clinical Oncology, 2016
- Role of lipids in the formation and maintenance of the cutaneous permeability barrierBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2014
- Epidermal growth factor receptor targeting in cancer: A review of trends and strategiesBiomaterials, 2013
- Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancerJournal of the American Academy of Dermatology, 2013
- Structure and function of the epidermis related to barrier propertiesClinics in Dermatology, 2012
- Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinionAnnals of Oncology, 2010
- Skin barrier function, epidermal proliferation and differentiation in eczemaJournal of Dermatological Science, 2006
- Ceramides and Skin FunctionAmerican Journal of Clinical Dermatology, 2003
- Aberrant Lipid Organization in Stratum Corneum of Patients with Atopic Dermatitis and Lamellar IchthyosisJournal of Investigative Dermatology, 2001